Central Nervous System Therapeutic Market

Central Nervous System Therapeutic Market Size, Share & Trends
Analysis Report and Segment Forecast, 2025| Grand View Research, Inc
“The global Central Nervous System (CNS) therapeutic market size was worth USD
77.2 billion in 2016 and is anticipated to grow at a CAGR of 5.9% during the
forecast period.”
The global Central Nervous System Therapeutic Market is expected to reach USD 128.9 billion by 2025,
according to a new report by Grand View Research, Inc. Rising prevalence of mental illnesses and increasing
awareness regarding psychiatric disorders are driving market growth. In addition, expanding geriatric
population and rising prevalence of lifestyle-associated CNS disorders are increasing global demand for central
nervous system therapeutics.
Mental health segment accounted for the largest market share in 2016. It is expected to retain its dominance
over the forecast period owing to developing therapeutic options for mental diseases such as personality
disorders and binge eating disorders. This segment is followed by degenerative disorders segment. There is
growing awareness regarding neurodegenerative diseases owing to increase in initiatives by government and
nongovernment organizations, such as Alzheimer’s and Related Disorders Society of India. These organizations
conduct awareness campaigns and conferences, such as Asia Pacific Conference of ADI at New Delhi and Kerala
State Initiative on Dementia, which encourage the adoption of treatment for degenerative and mental
disorders.
Cancer segment is expected to emerge as the fastest growing segment in the Central Nervous System
therapeutics market. High demand for effective treatment and a large number of drugs in later phases of
clinical trials are factors expected to propel the growth of the segment.
To request a sample copy or view summary of this report, click the link below:
http://www.grandviewresearch.com/industry-analysis/central-nervous-system-cns-therapeutic-market
Follow Us:
Further Key Findings from the Report Suggest:

Global mental health therapeutics revenue accounted for 48% share in 2016 and is expected to grow at
a significant rate from 2016 to 2025

Global demand for the treatment of Parkinson’s and Alzheimer’s diseases is anticipated to witness
extensive growth over the next 9 years

The industry in Asia Pacific is expected to report fastest growth over the forecast period owing to
various developments across major economies of the region, especially in the mental health sector.

Key players including Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.; Biogen, Inc.; Johnson & Johnson
Services, Inc.; Eli Lilly and Company; and Novartis AG led the global CNS disease treatment market by
capturing a majority share
Grand View Research has segmented the global Central Nervous System (CNS) therapeutics market on the basis
of disease and region:
CNS Therapeutics Disease Outlook (Revenue, USD Million, 2014 - 2025)

Neurovascular Disease

Trauma

Mental Health

o
Anxiety Disorders
o
Mood Disorders
o
Substance Abuse Disorders
o
Others (Insomnia, Binge Eating Disorder)
Degenerative
o
Alzheimer's Disease
o
Parkinson’s Disease
o
Multiple Sclerosis
o
Others

Infections

Cancer
Follow Us:
CNS Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025)





North America
o
U.S.
o
Canada
Europe
o
Germany
o
U.K
Asia Pacific
o
India
o
Japan
Latin America
o
Brazil
o
Mexico
Middle East & Africa
o
Follow Us:
South Africa
Table of Content of Central Nervous System (CNS) Therapeutic Market
Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Data Analysis
1.3 Approaches for Market Estimation
1.3.1 Approach 1: Demand Analysis& Bottom up Approach
1.3.2 Approach 2: Top-down market estimation
1.3.3 Approach 3: Commodity flow and bottom up market estimation
1.3.4 Approach 4: KoL perspective based market sizing
Chapter 2 Executive Summary
2.1 Market Segmentation & Scope
Chapter 3 CNS Therapeutics Market Variables, Trends, & Scope
3.1 Market Segmentation & Scope
3.1.1 Market Driver Analysis
3.1.1.1 Increasing prevalence of CNS disorder
3.1.1.2 Patent cliff
3.1.1.3 Introduction of novel drug delivery system in CNS disorders
3.1.2 Market Restraint Analysis
3.1.2.1 High treatment cost
3.2 Penetration & Growth Prospect Mapping
3.3 CNS Therapeutics -SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
3.4 Industry Analysis - Porter’s
Chapter 4 CNS Therapeutics Market: Disease Estimates & Trend Analysis
4.1 CNS Therapeutics Market: Disease Movement Analysis
4.2 Neurovascular Diseases
4.2.1 Neurovascular diseases market, 2014 - 2025 (USD Million)
4.3 Mental Health
4.3.1 Mental health market, 2014 - 2025 (USD Million)
4.3.2 Anxiety Disorders market, 2014 - 2025 (USD Million)
Follow Us:
4.3.2.1 Anxiety disorder market, 2014 - 2025 (USD Million)
4.3.3 Mood Disorder
4.3.3.1 Mood disorder market, 2014 - 2025 (USD Million)
4.3.4 Substance Abuse Disorder
4.3.4.1 Substance abuse disorder market, 2014 - 2025 (USD Million)
4.3.5 Others (Attention Deficit, Personality, Insomnia, BED, etc.)
4.3.5.1 Others market, 2014 - 2025 (USD Million)
4.4 Degenerative Disorders
4.4.1 Degenerative disorders market, 2014 - 2025 (USD million)
4.4.2 Alzheimer's Disease
4.4.2.1 Alzheimer's Disease market, 2014 - 2025 (USD Million)
4.4.3 Parkinson’s Disease
4.4.3.1 Parkinson’s disease market, 2014 - 2025 (USD Million)
4.4.4 Multiple Sclerosis
4.4.4.1 Multiple sclerosis market, 2014 - 2025 (USD Million)
4.4.5 Others
4.4.5.1 Others market, 2014 - 2025 (USD Million)
Chapter 5 CNS Therapeutics Market: Regional Estimates & Trend Analysis, by Diseases
5.1 CNS Therapeutics : Region Movement Analysis
5.2 North America
5.2.1 North America CNS therapeutics market, 2014 - 2025 (USD Million)
5.2.2 U.S.
5.2.2.1 U.S. CNS therapeutics market, 2014 - 2025 (USD Million)
5.2.3 Canada
5.2.3.1 Canada CNS therapeutics market, 2014 - 2025 (USD Million)
5.3 Europe
5.3.1 Europe CNS therapeutics market, 2014 - 2025 (USD Million)
5.3.2 Germany
5.3.2.1 Germany CNS therapeutics market, 2014 - 2025 (USD Million)
5.3.3 UK
5.3.3.1 UK CNS therapeutics market, 2014 - 2025 (USD Million)
Follow Us:
5.4 Asia Pacific
5.4.1 Asia Pacific CNS therapeutics market, 2014 - 2025 (USD Million)
5.4.2 China
5.4.2.1 China CNS therapeutics market, 2014 - 2025 (USD Million)
5.4.3 India
5.4.3.1 India CNS therapeutics market, 2014 - 2025 (USD Million)
5.5 Latin America
5.5.1 Latin America CNS therapeutics market, 2014 - 2025 (USD Million)
5.5.2 Brazil
5.5.2.1 Brazil CNS therapeutics market, 2014 - 2025 (USD Million)
5.5.3 Mexico
5.5.3.1 Mexico CNS therapeutics market, 2014 - 2025 (USD Million)
5.6 MEA
5.6.1 MEA CNS therapeutics market, 2014 - 2025 (USD Million)
5.6.2 South Africa
5.6.2.1 South Africa CNS therapeutics market, 2014 - 2025 (USD Million)
Chapter 6 Competitive Landscape
6.1 Market Participation Categorization
6.2 Company Profiles
6.2.1 Pfizer, Inc.
6.2.1.1 Company overview
6.2.1.2 Financial performance
6.2.1.3 Product benchmarking
6.2.1.4 Product pipelines
6.2.1.5 Strategic initiatives
6.2.2 Biogen, Inc.
6.2.2.1 Company overview
6.2.2.2 Financial performance
6.2.2.3 Product benchmarking
6.2.2.4 Product pipelines
6.2.2.5 Strategic initiatives
Follow Us:
6.2.3 Otsuka Pharmaceutical Co., Ltd.
6.2.3.1 Company overview
6.2.3.2 Financial performance
6.2.3.3 Product benchmarking
6.2.3.4 Product pipelines
6.2.3.5 Strategic initiatives
6.2.4 Eli Lily
6.2.4.1 Company overview
6.2.4.2 Financial performance
6.2.4.3 Product benchmarking
6.2.4.4 Product pipelines
6.2.4.5 Strategic initiatives
6.2.5 Merck & Co.
6.2.5.1 Company overview
6.2.5.2 Financial performance
6.2.5.3 Product benchmarking
6.2.5.4 Product pipelines
6.2.6 Astra Zeneca
6.2.6.1 Company overview
6.2.6.2 Financial performance
6.2.6.3 Product benchmarking
6.2.6.4 Product pipelines
6.2.7 Shire PLC
6.2.7.1 Company overview
6.2.7.2 Financial performance
6.2.7.3 Product benchmarking
6.2.7.4 Product pipelines
6.2.7.5 Strategic initiatives
6.2.8 Novartis AG
6.2.8.1 Company overview
6.2.8.2 Financial performance
Follow Us:
6.2.8.3 Product pipelines
6.2.8.4 Strategic initiatives
6.2.9 Teva Pharmaceuticals
6.2.9.1 Company overview
6.2.9.2 Financial performance
6.2.9.3 Product benchmarking
6.2.9.4 Product pipelines
6.2.10 Johnson & Johnson
6.2.10.1 Company overview
6.2.10.2 Financial performance
6.2.10.3 Product benchmarking
6.2.10.4 Strategic initiatives
About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed business decisions, the company offers
market intelligence studies ensuring relevant and fact-based research across a range of industries including
technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: [email protected]
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/
Follow Us:

The global Central Nervous System (CNS) therapeutic market size was worth USD 77.2 billion in 2016 and is anticipated to grow at a CAGR of 5.9% during the forecast period.

Download Report